Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLPT NYSE:FAII NASDAQ:FDMT NASDAQ:TCMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLPTClearPoint Neuro$10.95+0.2%$11.02$9.76▼$19.22$311.31M0.89313,877 shs223,247 shsFAIIFortress Value Acquisition Corp. II$9.36$9.01▼$13.05$72.45MN/A845,837 shs376,711 shsFDMT4D Molecular Therapeutics$6.97$5.47$2.23▼$17.41$325.50M2.85859,078 shs354,874 shsTCMDTactile Systems Technology$13.69+1.8%$11.47$8.61▼$21.10$305.18M1.03272,439 shs133,212 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLPTClearPoint Neuro-1.09%+4.19%+1.02%-17.76%-8.07%FAIIFortress Value Acquisition Corp. II0.00%0.00%0.00%0.00%-71.76%FDMT4D Molecular Therapeutics-4.13%+13.15%+23.80%+55.93%-53.75%TCMDTactile Systems Technology-0.07%+1.05%+9.53%+29.95%+1.89%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLPTClearPoint Neuro$10.95+0.2%$11.02$9.76▼$19.22$311.31M0.89313,877 shs223,247 shsFAIIFortress Value Acquisition Corp. II$9.36$9.01▼$13.05$72.45MN/A845,837 shs376,711 shsFDMT4D Molecular Therapeutics$6.97$5.47$2.23▼$17.41$325.50M2.85859,078 shs354,874 shsTCMDTactile Systems Technology$13.69+1.8%$11.47$8.61▼$21.10$305.18M1.03272,439 shs133,212 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLPTClearPoint Neuro-1.09%+4.19%+1.02%-17.76%-8.07%FAIIFortress Value Acquisition Corp. II0.00%0.00%0.00%0.00%-71.76%FDMT4D Molecular Therapeutics-4.13%+13.15%+23.80%+55.93%-53.75%TCMDTactile Systems Technology-0.07%+1.05%+9.53%+29.95%+1.89%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLPTClearPoint Neuro 3.00Buy$19.6779.60% UpsideFAIIFortress Value Acquisition Corp. II 0.00N/AN/AN/AFDMT4D Molecular Therapeutics 2.64Moderate Buy$30.40336.15% UpsideTCMDTactile Systems Technology 2.40Hold$13.50-1.39% DownsideCurrent Analyst Ratings BreakdownLatest FAII, FDMT, CLPT, and TCMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/30/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating8/14/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating8/12/2025FDMT4D Molecular TherapeuticsRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$44.00 ➝ $38.008/12/2025FDMT4D Molecular TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.008/5/2025TCMDTactile Systems TechnologyWilliam BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/5/2025TCMDTactile Systems TechnologyB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$12.00 ➝ $13.008/1/2025CLPTClearPoint NeuroStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $9.008/1/2025FDMT4D Molecular TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.007/29/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating7/12/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating7/3/2025FDMT4D Molecular TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.00(Data available from 9/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLPTClearPoint Neuro$31.39M9.92N/AN/A$0.92 per share11.90FAIIFortress Value Acquisition Corp. IIN/AN/AN/AN/A$0.12 per shareN/AFDMT4D Molecular Therapeutics$40K8,137.48N/AN/A$11.05 per share0.63TCMDTactile Systems Technology$298.85M1.02$1.10 per share12.44$9.03 per share1.52Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLPTClearPoint Neuro-$18.91M-$0.81N/AN/AN/A-66.15%-94.44%-51.58%11/6/2025 (Estimated)FAIIFortress Value Acquisition Corp. II-$13.61MN/A0.00N/AN/AN/AN/AN/AN/AFDMT4D Molecular Therapeutics-$160.87M-$3.53N/AN/AN/A-594,375.81%-40.15%-36.43%11/12/2025 (Estimated)TCMDTactile Systems Technology$16.96M$0.6222.0816.30N/A5.06%7.72%5.59%11/3/2025 (Estimated)Latest FAII, FDMT, CLPT, and TCMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025CLPTClearPoint Neuro-$0.20-$0.21-$0.01-$0.21$9.20 million$9.22 million8/11/2025Q2 2025FDMT4D Molecular Therapeutics-$0.88-$0.98-$0.10-$0.98$0.52 million$0.01 million8/4/2025Q2 2025TCMDTactile Systems Technology$0.09$0.14+$0.05$0.14$73.93 million$78.91 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLPTClearPoint NeuroN/AN/AN/AN/AN/AFAIIFortress Value Acquisition Corp. IIN/AN/AN/AN/AN/AFDMT4D Molecular TherapeuticsN/AN/AN/AN/AN/ATCMDTactile Systems TechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLPTClearPoint Neuro1.467.306.45FAIIFortress Value Acquisition Corp. IIN/A0.090.09FDMT4D Molecular TherapeuticsN/A8.758.75TCMDTactile Systems Technology0.113.793.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLPTClearPoint Neuro30.08%FAIIFortress Value Acquisition Corp. II64.25%FDMT4D Molecular Therapeutics99.27%TCMDTactile Systems Technology83.43%Insider OwnershipCompanyInsider OwnershipCLPTClearPoint Neuro6.11%FAIIFortress Value Acquisition Corp. IIN/AFDMT4D Molecular Therapeutics9.60%TCMDTactile Systems Technology2.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLPTClearPoint Neuro11028.43 million26.69 millionOptionableFAIIFortress Value Acquisition Corp. IIN/A43.13 millionN/ANot OptionableFDMT4D Molecular Therapeutics12046.70 million42.22 millionOptionableTCMDTactile Systems Technology1,03722.29 million21.74 millionOptionableFAII, FDMT, CLPT, and TCMD HeadlinesRecent News About These CompaniesPunch & Associates Investment Management Inc. Has $3.73 Million Stake in Tactile Systems Technology, Inc. $TCMDSeptember 9 at 5:31 AM | marketbeat.comShould Value Investors Buy Tactile Systems Technology (TCMD) Stock?September 8 at 6:01 PM | zacks.comInvenomic Capital Management LP Makes New Investment in Tactile Systems Technology, Inc. $TCMDSeptember 8 at 6:18 AM | marketbeat.comNuveen LLC Acquires New Holdings in Tactile Systems Technology, Inc. $TCMDSeptember 4, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Cuts Holdings in Tactile Systems Technology, Inc. $TCMDSeptember 3, 2025 | marketbeat.comTactile Systems Technology, Inc. (NASDAQ:TCMD) Receives $13.50 Consensus Price Target from AnalystsSeptember 3, 2025 | americanbankingnews.comTactile Systems Technology, Inc. $TCMD Shares Sold by Paradigm Capital Management Inc. NYSeptember 2, 2025 | marketbeat.comRussell Investments Group Ltd. Trims Stock Holdings in Tactile Systems Technology, Inc. $TCMDSeptember 2, 2025 | marketbeat.comReturns At Tactile Systems Technology (NASDAQ:TCMD) Are On The Way UpSeptember 1, 2025 | finance.yahoo.comTactile Systems Technology, Inc. (NASDAQ:TCMD) Receives Consensus Recommendation of "Hold" from BrokeragesSeptember 1, 2025 | marketbeat.comMartingale Asset Management L P Grows Stock Position in Tactile Systems Technology, Inc. $TCMDAugust 27, 2025 | marketbeat.comAre Investors Undervaluing Tactile Systems Technology (TCMD) Right Now?August 22, 2025 | zacks.comTactile Systems Technology, Inc. $TCMD Shares Sold by Tocqueville Asset Management L.P.August 20, 2025 | marketbeat.comTactile Systems Technology, Inc. (NASDAQ:TCMD) CEO Sheri Louise Dodd Sells 7,762 SharesAugust 14, 2025 | marketbeat.comKoss Olinger Consulting LLC Takes Position in Tactile Systems Technology, Inc. (NASDAQ:TCMD)August 11, 2025 | marketbeat.comBlair William & Co. IL Reduces Position in Tactile Systems Technology, Inc. (NASDAQ:TCMD)August 10, 2025 | marketbeat.comTactile Systems Technology (NASDAQ:TCMD) Upgraded by Wall Street Zen to Buy RatingAugust 10, 2025 | marketbeat.comTactile Systems Technology, Inc. (NASDAQ:TCMD) Q2 2025 Earnings Call TranscriptAugust 7, 2025 | msn.comIs Tactile Systems Technology (TCMD) Stock Undervalued Right Now?August 6, 2025 | zacks.comTactile Systems Technology (TCMD) Just Overtook the 20-Day Moving AverageAugust 6, 2025 | zacks.comTactile Systems Technology (TCMD) Recently Broke Out Above the 50-Day Moving AverageAugust 6, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFAII, FDMT, CLPT, and TCMD Company DescriptionsClearPoint Neuro NASDAQ:CLPT$10.95 +0.02 (+0.18%) Closing price 04:00 PM EasternExtended Trading$11.08 +0.14 (+1.23%) As of 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.Fortress Value Acquisition Corp. II NYSE:FAIIFortress Value Acquisition Corp. II does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.4D Molecular Therapeutics NASDAQ:FDMT$6.97 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$6.93 -0.04 (-0.57%) As of 06:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.Tactile Systems Technology NASDAQ:TCMD$13.69 +0.24 (+1.78%) Closing price 04:00 PM EasternExtended Trading$13.70 +0.01 (+0.04%) As of 04:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema in the home setting; and Entre Plus System, a portable pneumatic compression device for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers. The company also provides Kylee, a mobile application to help patients learn about lymphedema, track their symptoms, and treatment, as well as to share their progress with their doctor; and AffloVest, a portable high frequency chest wall oscillation vest to treat patients with retained pulmonary secretions resulting from bronchiectasis, cystic fibrosis, and various neuromuscular disorders. Tactile Systems Technology, Inc. was incorporated in 1995 and is headquartered in Minneapolis, Minnesota. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Casey’s General Stores: Investors Win With CASY at the Bat Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing The Quiet Before the Catalyst: Vertical Aerospace's Next Move Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver Insiders Sell These High-Quality Stocks: Why Investors Shouldn’t 2 Small-Cap Dividend-Paying Retailers to Buy and Hold for 2026 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
